Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy

J Nanobiotechnology. 2023 Nov 24;21(1):444. doi: 10.1186/s12951-023-02227-0.

Abstract

Intestinal epithelia impairment of inflammatory bowel disease (IBD) leads to the leakage of bacteria and antigens and the consequent persistent immune imbalance. Restoring the epithelial barrier is a promising therapeutic target but lacks effective and safe clinical interventions. By identifying the catalase (CAT) presence in the IBD pathological environment, we herein develop a CAT-catalyzed pathologically coating on the damaged epithelial barrier to inhibit intestinal leakage for IBD therapy. With the codelivery of CaO2 (a CAT substrate) and dopamine, the nanosystem can enable CAT-catalyzed oxygen (O2) production and in-situ polymerization of dopamine and then yield a thin and integrative polydopamine (PDA) coating on the intestinal barrier due to the highly adhesive property of PDA. In vivo study demonstrates that PDA coating provides not only a protective barrier by restricting intestinal leakage but also a favorable anti-inflammation effect. Beyond drug management, this work provides a physical repair strategy via catalyzed coating for IBD therapy.

Keywords: Inflammatory bowel Disease; Intestinal barrier; Pathological catalysis; Polydopamine coating.

MeSH terms

  • Catalysis
  • Dopamine*
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Intestinal Mucosa

Substances

  • Dopamine